Search
Humacyte Inc
HUMAAdd to Watchlist
0.710USD
+0.037+5.56%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
191.44MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.56%
5 Days
+14.52%
1 Month
-48.92%
6 Months
-27.18%
Year to Date
-26.08%
1 Year
-69.26%
Key Figures
0.700Open
0.735High
12.89MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
6.68%Turnover Ratio
0.673Prev. Close
0.694Low
7.53MTurnover
LossP/E Static
44.08P/B
0.00%Div Yield TTM
-71.47%ROA
2.93052wk High
0.85Volume Ratio
-148.70MNet Profit
193.00MShares
-0.6449EPS TTM
2.42Beta
-409.47%ROE
0.54752wk Low
6.10%Amplitude
-311.72%Gross Margin
191.44MMarket Cap
-8.42Reward/Risk
6.17%Risk Rate
TradingKey Stock Score of Humacyte Inc
Currency: USD Updated: 2026-07-02Key Insights
Humacyte Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 159 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 2.05.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Humacyte Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Humacyte Inc Highlights
StrengthsRisks
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
Growing
The company is in a growing phase, with the latest annual income totaling USD 2.04M.
Overvalued
The company’s latest PE is -1.10, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 72.10M shares, decreasing 3.18% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 6.48K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 2.05.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
2.050
Target Price
+156.60%
Upside Space
Humacyte Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Humacyte Inc Info
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.
Ticker SymbolHUMA
CompanyHumacyte Inc
CEONiklason (Laura E)
Websitehttps://humacyte.com/
Related Instruments
+1.62%
+3.50%
+3.96%
+3.72%
+3.31%
+6.14%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52927.700
+85.200 (+0.16%)
29617.200
+305.800 (+1.04%)
7503.800
+32.300 (+0.43%)
14964.000
+161.000 (+1.09%)
69664.000
+1516.000 (+2.23%)
6380.300
+27.500 (+0.43%)
68.433
+0.089 (+0.13%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4177.680
+55.770 (+1.35%)
FAQs
What is the current price of Humacyte Inc (HUMA)?
The current price of Humacyte Inc (HUMA) is 0.71.
What is the symbol of Humacyte Inc?
The ticker symbol of Humacyte Inc is HUMA.
What is the 52-week high of Humacyte Inc?
The 52-week high of Humacyte Inc is 2.93.
What is the 52-week low of Humacyte Inc?
The 52-week low of Humacyte Inc is 0.55.
What is the market capitalization of Humacyte Inc?
The market capitalization of Humacyte Inc is 137.03M.
Is Humacyte Inc (HUMA) currently rated as Buy, Hold, or Sell?
According to analysts, Humacyte Inc (HUMA) has an overall rating of Buy, with a price target of 2.05.
What is the Earnings Per Share (EPS TTM) of Humacyte Inc (HUMA)?
The Earnings Per Share (EPS TTM) of Humacyte Inc (HUMA) is -0.26.